# Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

> **NCT03373435** · PHASE2 · COMPLETED · sponsor: **Eiger BioPharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Postbariatric Hypoglycemia

## Interventions

- **DRUG:** exendin 9-39
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03373435
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-19
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-03-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373435, "Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03373435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*